Traditional Chinese medicine composition for treating jaundice hepatitis

Abstract

The invention discloses a traditional Chinese medicine composition for treating jaundice hepatitis. The composition is composed of the following raw materials in parts by weight: 20 to 25 parts of honeysuckle flower, 10 to 12 parts of ephedra stem, 4 to 5 parts of patrinia herb, 2 to 4 parts of magnolia cortex flower, 4 to 6 parts of processed pinellia ternate, 5 to 10 parts of pepperweed seed, 3 to 5 parts of radix astragali, 2 to 4 parts of albizia bark, 5 to 10 parts of balloonflower root, 3 to 5 parts of heartleaf houttuynia herb, 2 to 4 parts of reynoutria japonica, 1 to 3 parts of folium isatidis, 3 to 5 parts of artemisia capillary, 2 to 3 parts of common fennel fruit, 4 to 6 parts of arctium fruit, 2 to 4 parts of gypsophila paniculata, 1 to 3 parts of melica scabrosa, 1 to 3 parts of mallotus paniculatus, 1 to 2 parts of clerodendranthus spicatus, 1 to 2 parts of solanum incanum, and 2 to 4 parts of mallotus repandus. The medicinal raw materials mentioned above can well cooperate with each other to generate a synergetic effect, and thus the traditional Chinese medicine composition has the functions of clearing heat, draining dampness, removing toxicity and jaundice, resolving stasis, dissipating binds, draining the gallbladder, protecting liver from toxins, dispelling stasis, and promoting regeneration, is suitable for treating jaundice hepatitis, and has the characteristics of short treatment course, prominent effect, and complete cure.

Description

technical field [0001] The invention relates to the field of Chinese herbal medicines, in particular to a Chinese medicine composition for treating icteric hepatitis. Background technique [0002] Jaundice hepatitis is caused by hepatitis virus damage to liver cells, liver tissue destruction and remodeling, bile duct obstruction, resulting in increased blood conjugated bilirubin and unconjugated bilirubin, resulting in skin, mucous membranes and eyeball sclera There is no clear treatment plan for jaundice hepatitis clinically. Modern medicine often fails to achieve the expected effect and cannot find a suitable treatment method for a certain clinical symptom. Western medicine mainly uses antiviral therapy. However, the currently commonly used antiviral drugs have their own shortcomings in varying degrees. For example, short-acting interferon has the disadvantages of poor curative effect, large side effects, and low virus clearance rate. Although long-acting interferon has im...

AI Technical Summary

Problems solved by technology

[0002] Jaundice hepatitis is caused by hepatitis virus damage to liver cells, liver tissue destruction and remodeling, bile duct obstruction, resulting in increased blood conjugated bilirubin and unconjugated bilirubin, resulting in skin, mucous membranes and eye sclera There is no clear treatment plan for jaundice hepatitis clinically. Modern medicine often fails to achieve the expected effect and cannot find a suitable treatment method for a certain clinical symptom. Western medicine mainly uses antiviral therapy. However, the currently commonly used antiviral drugs have their own shortcomings in varying degrees. For example, short-acting interferon has the disadvantages of poor curative effect, large side effects, and low virus clearance rate. Although long-acting interferon has improved curative effect, it still cannot achieve the desired effect. Although nucleoside analogues such as heptin, adefovir dipivoxil, and entecavir have few side effects and are effective in inhibiting the virus, there are problems such as virus mutation and recurrence of the disease after drug withdrawal; Wet, detoxification and anti-yellow decoction, the cost is high, and the adverse reactions are obvious, and the virus clearance rate is not high, the drug utilization rate is low, and there are also complex medications, troublesome decoction, bitter taste, inconvenient to take and carry, long-term application stimulation Disadvantages such as gastrointestinal tract, unacceptable to patients